Substance · official US FDA label
Nitrate d'éconazole (econazole)
42 medicines listed on Vimpia contain it, alone or combined. Below, the official US FDA label for econazole, unchanged.
Want to buy it?
Trouver shows the pharmacies near you that have it right now, and their prices. The reservation pages are in French.
This is a US label.
The official US FDA label for econazole (published as ECONAZOLE NITRATE), effective June 22, 2026, describes products sold in the United States. The medicine sold in DR Congo may differ in strength, form or approved uses: ask a pharmacist or a doctor.
Official US FDA label for econazole
Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. The full label on DailyMed.
Uses
INDICATIONS AND USAGE Econazole nitrate cream is indicated for topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis, Microsporum audouini, Microsporum gypseum, and Epidermophyton floccosum , in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor.
Dosage
US dosage, for products sold in the United States. For a medicine bought in DR Congo, follow its box, its leaflet or your pharmacist.
DOSAGE AND ADMINISTRATION Sufficient econazole nitrate cream, 1 % should be applied to cover affected areas once daily in patients with tinea pedis, tinea cruris, tinea corporis, and tinea versicolor, and twice daily (morning and evening) in patients with cutaneous candidiasis. Early relief of symptoms is experienced by the majority of patients and clinical improvement may be seen fairly soon after treatment is begun; however, candidal infections and tinea cruris and corporis should be treated for two weeks and tinea pedis for one month in order to reduce the possibility of recurrence. If a patient shows no clinical improvement after the treatment period, the diagnosis should be redetermined. Patients with tinea versicolor usually exhibit clinical and mycological clearing after two weeks of treatment.
Warnings and precautions
WARNINGS Econazole nitrate cream is not for ophthalmic use.
Side effects
ADVERSE REACTIONS During clinical trials, approximately 3% of patients treated with econazole nitrate cream, 1 % reported side effects thought possibly to be due to the drug, consisting mainly of burning, itching, stinging, and erythema. One case of pruritic rash has also been reported.
Medicines that contain it
Names as they are sold. A medicine without an English page links to its French page.
- ECONAZOLE ARROW 1 %, crème
- ECONAZOLE ARROW 1 %, poudre pour application cutanée
- ECONAZOLE ARROW 1 %, solution pour application cutanée
- ECONAZOLE ARROW 1 %, émulsion pour application cutanée
- ECONAZOLE ARROW L.P. 150 mg, ovule à libération prolongée
- ECONAZOLE BIOGARAN L.P. 150 mg, ovule à libération prolongée
- ECONAZOLE CRISTERS L.P. 150 mg, ovule à libération prolongée
- ECONAZOLE EG 1 %, poudre pour application cutanée
- ECONAZOLE EG 1 %, solution pour application cutanée
- ECONAZOLE EG 1 %, émulsion pour application cutanée
- ECONAZOLE EG L.P. 150 mg, ovule à libération prolongée
- ECONAZOLE SANDOZ 1 POUR CENT, poudre pour application cutanée
- ECONAZOLE SANDOZ L.P. 150 mg, ovule à libération prolongée
- ECONAZOLE TEVA L.P. 150 mg, ovule à libération prolongée
- ECONAZOLE TEVA SANTE 1 POUR CENT, crème
- ECONAZOLE TEVA SANTE 1 POUR CENT, poudre pour application cutanée
- ECONAZOLE TEVA SANTE 1 POUR CENT, solution pour application cutanée
- ECONAZOLE TEVA SANTE 1 POUR CENT, émulsion fluide pour application cutanée
- ECONAZOLE VIATRIS 1 %, crème
- ECONAZOLE VIATRIS 1 %, poudre pour application cutanée
- ECONAZOLE VIATRIS 1 %, émulsion pour application cutanée
- ECONAZOLE VIATRIS 1%, solution pour application cutanée
- ECONAZOLE VIATRIS L.P. 150 mg, ovule à libération prolongée
- ECONAZOLE ZENTIVA LP 150 mg, ovule à libération prolongée
- ECONAZOLE ZYDUS L.P. 150 mg, ovule à libération prolongée
- Fongicil 1% 0,01, crème
- Fongicil 150 mg, ovule
- Fongil 0,01, lait dermique
- FONGILEINE 1 POUR CENT, crème
- FONGILEINE 1 POUR CENT, poudre pour application cutanée
- GYNO-PEVARYL 150 mg, ovule
- GYNOPURA 1 %, crème pour application locale
- GYNOPURA L.P. 150 mg, ovule à libération prolongée
- MYCOAPAISYL 1 POUR CENT, crème
- MYCOSEDERMYL 1 POUR CENT, crème
- MYLEUGYNE 1 %, crème
- MYLEUGYNE L.P. 150 mg, ovule à libération prolongée
- PEVARYL 1 %, crème
- PEVARYL 1 %, poudre pour application cutanée en flacon poudreur
- PEVARYL 1 %, émulsion fluide pour application cutanée
- PEVARYL 1 POUR CENT, solution pour application locale en flacon pulvérisateur
- UNIVAGIL LP 150 mg, ovule à libération prolongée
Sources
- ●Labels: U.S. Food and Drug Administration, openFDA (public domain). Data provided by the U.S. Food and Drug Administration (openFDA), unchanged. DailyMed.
- ●English names of substances: RxNorm, U.S. National Library of Medicine.
- ●Marketing authorizations: register of the ACOREP, DR Congo.
- ●Essential medicines: national list of essential medicines of DR Congo (LNME).
- ●Composition: public medicines database of France (BDPM), ANSM, open licence.
Public information, for reference only: it does not replace the advice of a pharmacist or a doctor. Vimpia writes nothing about how to use a medicine and translates nothing: the label is the US FDA's, unchanged; names, composition and authorizations come from the official sources above.